Liron Sissman, MBA, Life Science Business Development Executive | Licensing | Strategic Partnering

Pharmaceutical Business Development Executive, Corporate M&A Transactions, Corporate Development, Licensing, Partnering, and Acquisitions, Due Diligence, Business Case Development, Financial Modeling and Valuations, Cross-Functional Leadership, Forecasting, Term Sheets, Negotiations, Raising Capital, Rare diseases, Biotech, eHealth, Consulting, MBA

AREAS OF EXPERTISE
Strategic in/out licensing and partnering	Leading cross-functional due diligence teams
Corporate Merger and Acquisition (M&A) transactions	C-Suite and BoD presentations and recommendations
Deal sourcing, structuring, negotiation, and execution	Multiple therapeutic areas including rare diseases

AREAS OF EXPERTISE

Strategic in/out licensing and partnering

Leading cross-functional due diligence teams

Corporate Merger and Acquisition (M&A) transactions

C-Suite and BoD presentations and recommendations

Deal sourcing, structuring, negotiation, and execution

Multiple therapeutic areas including rare diseases

IN BRIEF
Strategic and results-driven life science business development executive with a keen ability to craft innovative solutions in uncharted territory that optimize value and propel success. End-to-end deal execution representing companies of all scales. Adept at identifying and evaluating opportunities, navigating complex markets, and forging strategic collaborations that drive profitable growth in competitive markets.

IN BRIEF

Strategic and results-driven life science business development executive with a keen ability to craft innovative solutions in uncharted territory that optimize value and propel success. End-to-end deal execution representing companies of all scales. Adept at identifying and evaluating opportunities, navigating complex markets, and forging strategic collaborations that drive profitable growth in competitive markets.

SELECTED ACCOMPLISHMENTS
Led global out-licensing. Constructed, presented, and negotiated term sheets and licensing agreements resulting in signed agreements and a promotion to the position of Acting CFO while raising capital.
Negotiated favorable partnering terms for a Phase III asset resulting in significant cost savings and enhanced investor confidence. Drug was successfully launched four years later.
Engineered a strategic growth opportunity for a healthcare informatics company to re-use medical records to identify rare disease patients sooner and connect them with relevant clinical trials, resulting in a 35% business expansion which facilitated acquisition at an enhanced valuation. Supported a deal that closed at $275 million to a PE firm
One of a three-person C-Suite team presenting company to Wall Street, resulting in a $6 million private placement.
R&D portfolio management and optimization: Identified company core competencies for project selection. Created an interactive, predictive valuation model that incorporated insights and consistently ranked drug targets to streamline project selection. Applied model to prioritize a portfolio of 300 pipeline projects. Results: Improved profitability, optimized R&D resources, and helped increase annual FDA submissions from 5 to 14.
Led strategic initiatives, identified market opportunities, and secured commercial partners for pipeline assets through a competitive bidding process. Negotiated licensing and partnering agreements. Managed alliances.
Positioned a pharmaceutical company to complete a $10 million private placement. Prepared valuations and supporting business case resulting in a successful spinout.
Introduced an international biopharmaceutical company to US investors and potential partners, resulting in the overhaul of clinical trial design based on feedback.
Led global R&D teams through first project budgeting. Identified best practices and drove implementation across sites. Results: Reduced cost by 18%, streamlined operations by six months, and got budgets approved.
Led a Fortune 500 company through transition from earning-per-share growth targets to cash-based measures. Analyzed company's portfolio to optimize performance across seven business units. Mentored senior executives and trained analysts on Value Management. This increased business plan correlation with shareholder value creation by roughly 30%.

SELECTED ACCOMPLISHMENTS

Led global out-licensing. Constructed, presented, and negotiated term sheets and licensing agreements resulting in signed agreements and a promotion to the position of Acting CFO while raising capital.

Negotiated favorable partnering terms for a Phase III asset resulting in significant cost savings and enhanced investor confidence. Drug was successfully launched four years later.

Engineered a strategic growth opportunity for a healthcare informatics company to re-use medical records to identify rare disease patients sooner and connect them with relevant clinical trials, resulting in a 35% business expansion which facilitated acquisition at an enhanced valuation. Supported a deal that closed at $275 million to a PE firm

One of a three-person C-Suite team presenting company to Wall Street, resulting in a $6 million private placement.

R&D portfolio management and optimization: Identified company core competencies for project selection. Created an interactive, predictive valuation model that incorporated insights and consistently ranked drug targets to streamline project selection. Applied model to prioritize a portfolio of 300 pipeline projects. Results: Improved profitability, optimized R&D resources, and helped increase annual FDA submissions from 5 to 14.

Led strategic initiatives, identified market opportunities, and secured commercial partners for pipeline assets through a competitive bidding process. Negotiated licensing and partnering agreements. Managed alliances.

Positioned a pharmaceutical company to complete a $10 million private placement. Prepared valuations and supporting business case resulting in a successful spinout.

Introduced an international biopharmaceutical company to US investors and potential partners, resulting in the overhaul of clinical trial design based on feedback.

Led global R&D teams through first project budgeting. Identified best practices and drove implementation across sites. Results: Reduced cost by 18%, streamlined operations by six months, and got budgets approved.

Led a Fortune 500 company through transition from earning-per-share growth targets to cash-based measures. Analyzed company's portfolio to optimize performance across seven business units. Mentored senior executives and trained analysts on Value Management. This increased business plan correlation with shareholder value creation by roughly 30%.

EXPERIENCE
Paratek Pharmaceuticals, King of Prussia, PA A commercial-stage, biopharmaceutical company Vice President, Business Development	2024 - Current
Intercept Pharmaceuticals, Morristown, NJ A commercial-stage, biopharmaceutical company Global Head Business Development	2021 - 2024
Alyon Inc. Hackensack, NJ A US subsidiary of a Swiss pharmaceutical company Head of Business Development, North America	2016 - 2021
Luminant, LLC, Stamford, CT A life science business development consulting firm Business Development and Strategy Lead Consultant	2008 - 2016

EXPERIENCE

Paratek Pharmaceuticals, King of Prussia, PA
A commercial-stage, biopharmaceutical company
Vice President, Business Development

2024 - Current

Intercept Pharmaceuticals, Morristown, NJ
A commercial-stage, biopharmaceutical company
Global Head Business Development

2021 - 2024

Alyon Inc. Hackensack, NJ
A US subsidiary of a Swiss pharmaceutical company
Head of Business Development, North America

2016 - 2021

Luminant, LLC, Stamford, CT
A life science business development consulting firm
Business Development and Strategy Lead Consultant

2008 - 2016

ADDITIONAL RELEVANT EXPERIENCE
Strategic Growth Solutions, Park Ridge, NJ A business consulting company driving market expansion and brands success Principal
Taro Pharmaceuticals, USA, Hawthorne, NY A multinational pharmaceutical company Director, Financial Analysis and Strategic Planning
Public Service Electric and Gas (PSE&G), Newark, NJ A Fortune 500 electric and gas company Business Analysis Manager
Innapharma, Inc., Suffern, NY A pharmaceutical company and a contract research organization (CRO) Acting CFO

ADDITIONAL RELEVANT EXPERIENCE

Strategic Growth Solutions, Park Ridge, NJ
A business consulting company driving market expansion and brands success
Principal

Taro Pharmaceuticals, USA, Hawthorne, NY
A multinational pharmaceutical company
Director, Financial Analysis and Strategic Planning

Public Service Electric and Gas (PSE&G), Newark, NJ
A Fortune 500 electric and gas company
Business Analysis Manager

Innapharma, Inc., Suffern, NY
A pharmaceutical company and a contract research organization (CRO)
Acting CFO

EDUCATION
Master of Business Administration (MBA), Finance and International Business, Stern School of Business, New York University, New York, NY
Bachelor of Science (B.Sc.), Cum Laude in Chemistry, The Hebrew University, Jerusalem, Israel Discovered a new chemical Poly-Bis( -Diphenyl-Phosphinato)-Copper(II). Published an article in Inorganica Chemica Acta. Received three academic achievement awards.

EDUCATION

Master of Business Administration (MBA), Finance and International Business, Stern School of Business, New York University, New York, NY

Bachelor of Science (B.Sc.), Cum Laude in Chemistry, The Hebrew University, Jerusalem, Israel

Discovered a new chemical Poly-Bis( -Diphenyl-Phosphinato)-Copper(II). Published an article in Inorganica Chemica Acta. Received three academic achievement awards.

HONORS
Management Honors Program, Weizmann Institute, Rehovot, Israel Selected from the top ten graduates of all universities. Awarded a scholarship for excellence.

HONORS

Management Honors Program, Weizmann Institute, Rehovot, Israel
Selected from the top ten graduates of all universities. Awarded a scholarship for excellence.